Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent

Kim J., Kudisch M., da Silva N.R.K., Asada H., Aya-Shibuya E., Bloomer M.M., Mudumba S., Bhisitkul R.B., Desai T.A.

2018
Journal of Controlled Release

Therapeutic Area

Glaucoma
Technology

Drug Delivery

Affiliations

UC Berkeley-UCSF Graduate Program in Bioengineering, 1700 4th Street, San Francisco, CA 94158, United States; Department of Ophthalmology, University of California, San Francisco, 10 Koret Way, San Francisco, CA 94143, United States; Santen Pharmaceutical Co., Ltd., Nara RD CenterNara, Japan; Santen, Inc., 6401 Hollis Street, Suite 125, Emeryville, CA 94608, United States; Department of Bioengineering and Therapeutic Sciences, University of California, 1700 4th Street, San Francisco, CA 94158, United States

Related Publications

Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.

24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM

View all Glaucoma publications